Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02890069
Title A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

colorectal cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer


LCL161 + Spartalizumab

Everolimus + Spartalizumab

Panobinostat + Spartalizumab

Age Groups: adult | senior
Covered Countries USA | ESP | DEU

No variant requirements are available.